TABLE 2.
Pathogen |
Growth inhibition |
Other effects | |
wt | TR1341ΔFIL2 | ||
Candida albicans CCM 8186 | + | – | – |
Sacharomyces cerevisiae CCM 8191 | + | – | – |
Fusarium sp. BCCO 20_0605 | + | – | – |
Staphylococcus aureus DSM 346 | ++ | ++ | Hemolysis induced (only in the wt) |
Staph. aureus MRSA (clinical) | + | + | n.d. |
Bacillus subtilis CCM 1718 | + | + | – |
Streptococcus pneumoniae CCM 4424 | + | ++ | Formation of a capsule inhibited |
Moraxella catarrhalis (clinical) | + | + | – |
Neisseria pharyngis (clinical) | + | ++ | – |
Escherichia coli DSM 682 | – | – | – |
Klebsiella pneumoniae DSM 681 | – | – | – |
Pseudomonas aeruginosa DSM 50071 | – | – | Hemolysis induced (only in the wt) |
Growth inhibition zone of the pathogen indicated: “+”: a small inhibitory zone < 8 mm; “++”: a big inhibitory zone > = 8 mm; “−“: no growth inhibition; n.d., not defined. Other effects on the growth and characteristics given in the last column. For a typical picture see the Supplementary Figure S2.